Skip to main navigation Skip to search Skip to main content

PSI Pharma: A Randomized, Double-Blind, Placebo-controlled, Parallel Group, Mulitcenter Trial Evaluating the Efficacy and Safety of 2 Doses of Buloxibutid over 52 Weeks in People with Idiopathic Pulmonary Fibrosis

Project: Research

Project Details

StatusFinished
Effective start/end date07/8/25 → 07/23/25

Funding

  • Vicore Pharma AB: $13,703.75